Insurance Stopped Covering Mounjaro? What to Do Before Your Next Refill — and What It Costs Now

If your insurance stopped covering Mounjaro, ask the pharmacy whether the claim was rejected or just cost more. The fix depends on the denial and prescribed use. Lilly offers Mounjaro from $499 for four pens for eligible prescriptions; Zepbound's $299–$449 cash offers have separate rules. Contact your prescriber before you run out.

Two dates matter this fall. If you're on Medicare and your 2027 plan drops Mounjaro, open enrollment ends December 7, 2026, for coverage starting January 1, 2027. And Lilly's current savings cards end December 31, 2026.

Here's the catch most people miss: both $499 Mounjaro options require a prescription for type 2 diabetes. The table below shows the prices and the eligibility rules to check.

The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.

RX Index Decision Verdict: First find out whether this is a higher bill, a renewal problem, or a changed benefit, then work with your prescriber and plan on the next refill.

• Best for: Adults whose plan paid for Mounjaro before and now rejects a refill, denied a renewal, charges far more, or lists Mounjaro as dropped for 2027.
• Not ideal for: People who never had coverage (see does insurance cover Mounjaro for weight loss). If you're under 18, pregnant or planning a pregnancy, have type 1 diabetes or an eating-disorder history, have a personal or family history of medullary thyroid cancer or MEN 2, have had a serious allergic reaction to tirzepatide, or feel unwell right now, talk with your treating clinician first.
• The factor that matters most: The exact reason your claim changed, and the documented use on your prescription.

One honest limit up front: we can't see your claim, and no website can promise an approval. What we can do is help you ask the right person the right question today — and know what each path really costs if the answer is no.

Two questions that sort out your Mounjaro problem

Start with two questions. First, did your plan reject the claim, or was it accepted with a bigger amount for you to pay? Second, is type 2 diabetes the documented reason you take Mounjaro? Your answers point to a different fix and a different price.

Question 1: Rejected, or covered but pricier? Ask the pharmacist: "Did my insurance accept this claim, or reject it?" A claim is just the pharmacy's request for your plan to pay. If the plan accepted it, you may still have coverage — the jump may come from a new deductible (the amount you pay before your plan starts sharing costs), a higher tier, or a savings card that didn't run. That can be a covered-but-more-expensive fill rather than a loss of coverage. See why a covered Mounjaro fill can still cost more.

Question 2: Do you have type 2 diabetes? Mounjaro is FDA-approved to improve blood sugar in adults and children 10 and older with type 2 diabetes. Since August 2026, it's also approved to lower the risk of heart attack, stroke, and heart-related death in adults with type 2 diabetes at high risk. It isn't approved for weight loss alone. Plans can limit coverage by prescribed use, so start with the lane that matches the treatment you're asking about:

Having type 2 diabetes does not rule out a separate, clinician-approved weight-management option. These lanes organize the choices; they don't decide your eligibility.

Not sure if type 2 diabetes is in your chart? Ask your prescriber's office: "Is type 2 diabetes on my record, and which lab confirmed it?"

Our sorter below puts your answers together with your plan type. It shows the request to make, published price examples, and the conditions to check. It never converts your Mounjaro dose to a Zepbound dose. The full tables further down work without it.

Want to see it in action? Say you're 58, on Mounjaro 10 mg for type 2 diabetes through your employer. Your A1C dropped from 9.1% to 6.1%, and the renewal came back "criteria not met." That's the "My A1C is lower now" row: ask the plan which rule failed and have your prescriber address the renewal requirements, with the original diagnosis records and your A1C trend. While you wait, LillyDirect sells Mounjaro starting at $499 for four pens. (That's a made-up example, not a real reader.)

Why did my insurance stop covering Mounjaro? {#why-coverage-stopped}

Mounjaro coverage can stop for one of a handful of reasons: an approval expired, a renewal was denied, the plan switched its preferred drug, the plan now checks for a type 2 diabetes diagnosis, or the whole plan changed. A covered claim with a bigger bill is a different problem. The exact words on your pharmacy rejection or plan notice tell you which one you have.

Here's how to read what you were told. A prior authorization is a permission slip from your insurer — the plan has to say yes before it pays. A formulary is your plan's list of covered drugs. A pharmacy benefit manager (PBM), like CVS Caremark, Express Scripts, or OptumRx, runs the drug benefit for many plans.

If you don't know the reason yet, don't guess. Ask for the exact rejection and a written decision, then use the call script below. This table is a guide to the right request, not a ruling on your claim. For rejection codes, see what your pharmacy rejection code means, and for the difference between a dropped benefit and a paperwork rule, see benefit exclusion or prior-authorization problem.

The right next step depends on your situation: whether you have type 2 diabetes, your plan and its drug list, your state, FDA-approved or compounded treatment, injections or pills, and your budget. Compounded drugs are not FDA-approved. The RX Index's Find My GLP-1 Path tool is free, takes about 2 minutes, and needs no signup. Answer a few quick questions and see the GLP-1 paths and providers that fit your goals, budget, insurance, and situation. It can't read your claim or tell you whether your plan will pay — only your plan can.

See which GLP-1 path fits you

What should I do before my next refill? {#before-your-next-refill}

Contact your prescriber now with your plan's notice, your next refill date, and the date of your last dose. Then ask the pharmacy and plan for the exact reason in writing. A coverage fight can take weeks, so make a plan for your next dose before you run out.

Ask your prescriber or pharmacist what to do about a missed dose or longer gap, and use the label instructions for your exact Mounjaro product. A longer-gap restart plan is your prescriber's call.

If you have type 2 diabetes, your blood sugar matters more than the bill. Ask your prescriber how to keep your diabetes treatment steady while coverage gets sorted out. If you took Mounjaro for weight, continuity matters too. In the SURMOUNT-4 trial, adults with obesity or overweight and a related condition, without diabetes, first received tirzepatide for 36 weeks, reaching a maximum tolerated dose of 10 or 15 mg. Over the next 52 weeks, those switched to placebo gained an average 14% of their week-36 body weight, while those who continued lost another 5.5%. That study doesn't tell us what a short gap does. More on weight regain after stopping Mounjaro.

Don't stretch, skip, or space out doses on your own to make a supply last. If you feel seriously unwell, get medical care now — don't wait on insurance.

Call the pharmacy and plan with this script

Keep this beside you when you call the pharmacy, then the pharmacy-benefits number on your insurance card.

My plan paid for Mounjaro before, and this refill has changed. Did the claim go through with a higher cost to me, or was it rejected? Please give me the exact message and code, the product and quantity billed, and which plan received the claim. If coverage was denied, which written rule caused it? Is this a renewal, missing records, a required alternative, a drug-list change, or an excluded benefit? When did it change? What does my prescriber need to send, where should it go, and what's the deadline? Is any temporary supply or continued coverage available while this is reviewed, and what would I pay? Can I have a reference number and the instructions in writing?

Asking about a temporary supply isn't the same as having a right to one. Commercial plans vary; Medicare and Medicaid have their own rules, covered below.

Send your prescriber this message

Use your clinic's patient portal or secure message. Fill in the blanks privately after you copy it.

My Mounjaro refill is no longer covered or affordable. The pharmacy or plan says: [exact message]. My last covered fill was [date], my approval ends or ended [date or unknown], and I have [number or unknown] doses left. My last dose was [date]. I've attached the notice and any approval I have. Could your office check whether this needs a correction, a renewal, an exception, or an appeal? If the plan needs my original type 2 diabetes records or my treatment response, please include them. Please also tell me what to do before my supply runs out, and whether a different covered treatment is right for me. I'll follow your instructions about any gap or change.

Records to gather

Call record: For every call, write down the date and time, who you talked to, the reference number, whether the claim was accepted or rejected, the exact reason and rule, what your prescriber needs to do, the deadline, where to send it, any temporary-supply answer and cost, and when to follow up. Written answers beat phone promises.

My A1C is normal now. Can that get a renewal denied? {#a1c-renewal}

A renewal can be denied if the plan applies new-start criteria or lacks the records it requires. Some published policies have separate continuation rules that look for a steady dose and treatment response. A lower A1C — a blood test that shows average blood sugar over about 3 months — can support that response; it does not replace the original diagnosis records.

This is one of the most frustrating denials there is: the medicine worked, and now the plan says you don't qualify. Here's what published policies actually ask for at renewal:

These are examples. Your own plan's written rule is the one that counts, so ask for it. More on how first approvals and renewals differ, and plan-specific checklists for Cigna and CVS Caremark.

What to ask for, in one line: "Please review this as a continuation, with my original type 2 diabetes diagnosis and my A1C trend since starting." Your prescriber decides what to send. Ask for accurate records and coding. Never ask anyone to invent or misstate a diagnosis to obtain coverage.

What if I was taking Mounjaro for weight loss?

Mounjaro isn't FDA-approved for weight loss alone, and a plan can deny that use. Zepbound has the same active ingredient (tirzepatide), made by the same company. Alongside diet and physical activity, it is FDA-approved for long-term weight reduction in adults with obesity or overweight and a weight-related condition, and for moderate-to-severe obstructive sleep apnea in adults with obesity. It needs its own prescription, and your plan decides separately whether to cover it.

A plan paying for Mounjaro before doesn't mean it has to keep paying. "Off-label" just means prescribed for a use the FDA didn't approve. A plan may start requiring diagnosis records even if earlier fills were paid.

Here's what to ask your plan: "Does my plan cover Zepbound, or any weight-management medicine? What are the rules?" If your plan excludes weight-loss drugs entirely, switching brands won't fix that — the benefit itself is missing. If you have moderate-to-severe sleep apnea, ask whether your plan covers Zepbound for that use; see insurance for Zepbound and sleep apnea.

Whether Zepbound is right for you, and how to move between them, is your prescriber's decision. Our guide on switching from Mounjaro to Zepbound explains what to ask. If prediabetes or PCOS was your reason, see Mounjaro and prediabetes and Mounjaro and PCOS.

Should I ask for a correction, an exception, or an appeal?

It depends on what went wrong and which plan you have. Correct missing information while keeping track of the appeal deadline. Ask for an exception when a rule allows one, like a preferred-drug rule. File an appeal when you disagree with a decision, and follow the steps and deadline printed on your notice.

An exception asks the plan to cover a drug outside its normal list or rules. An appeal asks the plan to reconsider a denial. A peer-to-peer is a phone call between your prescriber and the plan's reviewer, when the plan offers one; do not assume it pauses your appeal deadline.

Asking can work. In 2023, New York's independent reviewers overturned two Aetna denials of Mounjaro after the patients' records showed other drugs had failed or caused side effects (case 202305-163384; case 202305-162818). Past cases don't predict yours, but they show that a well-documented request gets a real look.

If waiting for a standard decision could seriously harm your health, ask your prescriber whether to request a fast (expedited) review. The request should explain the medical risk of waiting, not just the refill date.

If your plan dropped weight-loss drugs, an appeal arguing you need the drug usually won't add the benefit back. You can still ask whether the rule was applied to you correctly. If you're on an employer plan, ask HR for the written notice of the change; employer plans covered by federal benefits law generally must send a summary of a major benefit cut within 60 days after it's adopted (29 CFR 2520.104b-3). Some midyear changes affecting the Summary of Benefits and Coverage require notice 60 days before they take effect (29 CFR 2590.715-2715). Ask which rule applies to your change.

Once you know the reason and your process, use our free GLP-1 appeal letter template — it's built for exactly this. More on formulary exceptions.

I'm on Medicare or Medicaid. What changes?

Medicare and Medicaid have their own rules, and the commercial savings cards described here exclude both. Many Medicare drug plans cover Mounjaro for type 2 diabetes. Medicare's $50 GLP-1 Bridge doesn't include Mounjaro.

Medicare

• Open enrollment runs October 15 – December 7, 2026. If your 2027 plan drops Mounjaro or adds new limits, check other plans in Medicare Plan Finder and switch by December 7 for coverage starting January 1, 2027 (Medicare.gov).
• Temporary supply. If you already take Mounjaro for a Part D-covered use, ask whether transition rules apply. Qualifying cases include joining a new plan or facing a negative formulary change at the start of the year. For a new plan, the transition window is the first 90 days of coverage; qualifying fills provide at least an approved month's supply unless the prescription is shorter. Safety and coverage exclusions still apply, and a continuing member may already have completed a transition before January (42 CFR 423.120; CMS transition guidance). Use that time to ask for an exception.
• Yearly cap. Your out-of-pocket cost for covered Part D drugs is capped at $2,100 in 2026 and $2,400 in 2027 (CMS 2027 announcement, Table V-2).
• What people pay. Lilly says about 8 in 10 Part D patients with Mounjaro coverage paid $0–$50 for a 28-day supply, based on IQVIA data from October 2024–September 2025 (Lilly). That is historical data, not a quote for your refill.
• The Bridge isn't for Mounjaro. The Medicare GLP-1 Bridge charges eligible patients $50 per monthly fill from July 1, 2026, through December 31, 2027, for Wegovy injection or tablets, Foundayo, and the Zepbound KwikPen when used for weight. Plan enrollment, clinical criteria, and prescriber prior authorization matter. Type 2 diabetes and other qualifying Part D indications, including moderate-to-severe sleep apnea, go through the regular Part D pathway. See Bridge eligibility.
• Cash. Eligible people with Medicare can use LillyDirect's Mounjaro self-pay offer, but what you pay doesn't count toward your Part D yearly cap (purchase terms).

Say you take Mounjaro for type 2 diabetes, turned 65 in September, and your new Part D plan's 2027 list doesn't include it. You'd compare plans in Plan Finder before December 7, and if you stay, ask about the temporary supply in January while your prescriber files an exception. (Hypothetical example.) More on what GLP-1s Medicare covers for diabetes.

Medicaid {#medicaid}

Coverage depends on your state and Medicaid plan's rules. If your Medicaid managed-care plan stops, reduces, or suspends a drug it already authorized, you may be able to keep it during your appeal. The drug must have been ordered by an authorized provider, the original approval must still be in effect, and both your appeal and request for continued benefits must be on time. Request continued benefits on or before the later of 10 calendar days after the plan sends the notice or the change's intended effective date. If you lose, the plan may be able to recover the cost under state policy and its contract (42 CFR 438.420). Call your plan the day you get the notice. See Mounjaro under Medicaid.

TRICARE and VA have their own rules: see TRICARE and Mounjaro and VA and Mounjaro.

If coverage doesn't come back, what will my next refill cost? {#price-options}

It depends on the prescription and offer rules. For eligible type 2 diabetes prescriptions, LillyDirect lists Mounjaro starting at $499 for four pens, and the commercial savings card can bring a noncovered fill to as low as $499. Weight-management-only prescriptions don't qualify for those Mounjaro offers; eligible Zepbound cash purchases cost $299 to $449 per 28 days by strength and refill terms.

Prices below were checked October 21, 2026. They're medicine prices, not a verified total for your care. Visits, labs, and supplies may be billed separately; ask what is included.

Lane A — you have type 2 diabetes

Lane B — you took Mounjaro for weight

Illustrative cost of 13 fills at the listed prices — not a future-year quote:

Thirteen 28-day quantities contain 364 days of medicine. Repeated late purchases span more than a year, so the late-refill row is not an annual budget or advice to space treatment. The Mounjaro card's 13-fill limit is per calendar year; it cannot fund 13 future monthly fills before its December 31, 2026 expiration. No 2027 card terms were verified. These are medicine-only illustrations, not guaranteed next-year prices.

The fine print, in plain words:

• Both $499 Mounjaro options need a prescription for an FDA-approved use (type 2 diabetes). LillyDirect's offer is for adults 18+ in the US or Puerto Rico; other purchase terms apply.
• The commercial Mounjaro and Zepbound card offers above require adult US/Puerto Rico residents with eligible commercial insurance and approved-use prescriptions. Government-program enrollment is excluded, and activation and other terms apply. The Mounjaro offers are for single-dose pens.
• Zepbound's direct Journey offer supplies four vials or one KwikPen per 28 days. The $299 2.5 mg price is for the starting strength, not a maintenance-price promise. Separate KwikPen savings cards have different limits; do not mix their terms with the direct purchase offer.
• You can't use the savings card and LillyDirect's self-pay on the same fill.
• If your employer plan uses an "alternate funding program," you may not be able to use the card. Ask your plan.
• LillyDirect lists Mounjaro as FSA/HSA eligible, though eligibility may vary by plan. Checkout acceptance, your insurance benefit, card eligibility, and IRS qualified-expense rules are separate questions. The card's savings can't be reimbursed from an HSA or FSA; only a qualifying amount you actually paid is a potential account expense. See Mounjaro and HSA/FSA.
• An unknown fee isn't a $0 fee. Ask your prescriber's office what visits and labs cost.

If even $449 or $499 is out of reach, tell your prescriber your real monthly limit. They may know a covered option that fits. You can also call Lilly Support Services at 1-800-545-5979 to ask about current affordability programs (Lilly). More detail: Mounjaro cash-payment options, Mounjaro savings-card rules, and Zepbound's costs by dose and form.

Do I need a new provider?

Usually not to start. Your current prescriber can submit a renewal request, request an exception, send records, or send a prescription to LillyDirect. A new provider can't make an excluded drug covered; it helps when your doctor won't handle the paperwork, doesn't manage this kind of care, or you need a new prescriber.

Already have a prescriber who'll help? Go straight to your plan or LillyDirect. You don't need a membership.

If you have type 2 diabetes and want to stay on Mounjaro

Ro doesn't offer Mounjaro, so it isn't a way to keep getting that prescription. If your own doctor can't help, Sesame lets you choose a clinician for online type 2 diabetes care. Its clinicians can prescribe Mounjaro when it's right for you and help with prior-authorization paperwork (Sesame). Visit or plan costs are separate from the medicine.

Need a clinician who can prescribe Mounjaro for type 2 diabetes and help with the paperwork? Sesame lets you pick your provider.

See Sesame's type 2 diabetes care options

If you're moving to Zepbound or another covered option

Ro doesn't fix exclusions, and its advertised Zepbound KwikPen medicine prices match LillyDirect's published offer prices; membership is extra. Where Ro helps is the legwork. Its free insurance check emails you a coverage report for the Ozempic pen, Wegovy pen, and Zepbound pen. It doesn't check Mounjaro, the Zepbound KwikPen, or pills (Ro). A report isn't an approval, prescription, or prior-authorization submission.

If your prescriber is considering the Zepbound pen for weight management and you want to know whether your commercial plan covers it, Ro's report is free. This check does not include KwikPen.

Check your Zepbound pen coverage with Ro

If you need a prescriber for a cash KwikPen, Ro lists the same $299–$449 Zepbound KwikPen prices as Lilly, plus its membership (Ro pricing). Get started for $39, then as low as $74/month with annual plan paid upfront. The annual prepaid membership works out to $888 ($74 × 12); the monthly plan is $149 a month. Medicine is billed separately. Ro advertises a refund of the first $39 if you're not eligible for GLP-1 treatment. Membership renews automatically; cancel at least 48 hours before renewal. Paid membership fees are generally nonrefundable.

Ro doesn't accept Medicaid members for treatment. If you're on Medicaid, start with your state plan. Medicare, Medicare supplement, and TRICARE members may qualify for certain cash-pay options after review (Ro insurance rules). More on how Ro compares with LillyDirect.

Need a prescriber for the Zepbound KwikPen and want everything in one place?

See Ro's Zepbound KwikPen pricing

What about compounded tirzepatide?

Compounded tirzepatide is not Mounjaro or Zepbound, and it is not FDA-approved. The FDA doesn't review compounded drugs for safety, effectiveness, or quality before they reach patients. The FDA confirmed the tirzepatide shortage was resolved in December 2024; the related temporary enforcement-discretion periods ended in 2025.

The FDA's April 1, 2026 reminder explains the restrictions on copies. For patient-specific compounding under section 503A, a prescriber relying on the patient-specific exception must document a formulation change that makes a significant difference for that patient; other requirements still apply. A lower price alone does not establish that difference (FDA guidance). Brand-name trial results do not establish the safety or effectiveness of a particular compounded product. And if you have type 2 diabetes, a compounded product isn't a stand-in for the diabetes plan you and your prescriber built.

If your clinician identifies a medical need and recommends a compounded option, our Embody review provides care background. Its price section needs an update; use Embody's current terms below for prices. Embody advertises compounded tirzepatide with clinician review. Its terms tie the lowest advertised monthly rate to a 12-month commitment. We couldn't confirm the amount you'd owe on day one or a complete state list. Its refund policy allows clinical review after checkout: paid terms are generally nonrefundable, with a limited medical-disqualification exception, and cancellation is due at least 72 hours before renewal. Confirm your selected plan, total, and state before paying. See also compounded vs. brand-name GLP-1s.

If your clinician recommends a compounded option for a medical need an approved drug cannot meet, and you've read the limits above (FDA):

See Embody's current pricing

How we checked this page

On October 21, 2026, we read the sources linked on this page and built the tables from them. We checked Lilly's Mounjaro savings-card terms, LillyDirect's Mounjaro and Zepbound pages and purchase terms, the Mounjaro prescribing information, CMS and Medicare.gov rules, HealthCare.gov and federal regulations, published Aetna and UnitedHealthcare criteria, New York's appeal records, NovoCare's Ozempic prices, Ro's and Sesame's own pages, Embody's terms and refund policy, IRS account guidance, and the FDA's compounding pages.

What we actually verified (October 21, 2026) | What we checked | What it confirms | What it can't tell you | |---|---|---| | Lilly Mounjaro Savings Card terms (CMAT-31122 08/2026) | $25 and $499 tiers, caps, approved-use rule, Dec 31, 2026 end | Your plan's decision or your card balance | | LillyDirect Mounjaro page and purchase terms | Starting at $499 for four pens; no insurance or deductible credit | Taxes, fees, or your final checkout | | Mounjaro prescribing information (revised 8/2026) | Approved uses, forms, missed-dose rule | What your prescriber will decide | | Lilly Zepbound terms (CMAT-05333 08/2026) | $299–$449 and the 45-day rule | Whether Zepbound fits you | | CMS, Medicare.gov, HealthCare.gov, federal regulations | Bridge rules, appeal clocks, temporary supply, Medicaid continued benefits | Whether your plan follows them correctly | | Aetna and UnitedHealthcare published criteria | How those plans judge renewals | Your plan's rules | | Ro, Sesame, and Embody pages and terms | Provider-stated services, prices, commitments, cancellation, and refund conditions | Your experience, clinical approval, or an unobserved checkout total | We did not see your plan's decision, test any provider, or complete any checkout.

Learn how we assess providers and treatment paths.

Questions about losing Mounjaro coverage

Why did insurance cover Mounjaro before and deny it now?

An approval can expire, your plan can change its drug list or add a diagnosis check, or a renewal can be missing records. Your past payment history doesn't tell you which one happened. Ask for the exact reason and the written rule.

Does a much higher price mean Mounjaro is no longer covered?

Not always. A covered claim can still leave a big bill if you haven't met your deductible or your coinsurance went up. Ask the pharmacy whether the claim was accepted with a cost to you or rejected, and what the price was before and after the savings card.

What if my doctor won't do a peer-to-peer review?

Ask whether the office can still resend the request with the missing records or write a supporting letter. Then check your notice for how you, or someone you authorize, can file the appeal. Do not assume waiting for a peer-to-peer extends your filing deadline; follow the written appeal instructions.

Will switching to Zepbound fix the coverage problem?

Maybe, but not automatically. For weight management, Zepbound is judged under your plan's weight-management rules, and an exclusion may still block coverage for that use. An approved sleep-apnea use is a separate coverage question. Ask your prescriber whether Zepbound fits you, then ask your plan about that exact prescription.

My A1C is normal now. Is that why I was denied?

The plan may have used new-start criteria or may be missing records. Aetna's cited continuation policy looks for historical diagnosis evidence, a steady maintenance period, and an A1C drop or another qualifying pathway. Ask your prescriber to address the exact renewal rule with the records it requires.

Can I still get Mounjaro for $25?

The $25 offer requires covered commercial insurance, an approved-use prescription, and all other card conditions, including adult eligibility and savings limits. If your plan doesn't cover it, the same card can bring a fill to as low as $499. The card excludes Medicare, Medicaid, and other government plans and ends December 31, 2026.

How much is Mounjaro without insurance now?

LillyDirect lists Mounjaro single-dose pens starting at $499 for 28 days (four pens) at every listed strength, for an eligible FDA-approved-use prescription. It cannot be submitted for insurance reimbursement or counted toward deductible, out-of-pocket limits, or Medicare Part D TrOOP. Taxes and fees may apply.

Does the Medicare GLP-1 Bridge cover Mounjaro?

No. The Bridge charges eligible patients $50 per monthly fill for Wegovy, Foundayo, or Zepbound KwikPen used for weight management. Mounjaro for type 2 diabetes goes through your regular Part D plan. If your 2027 plan drops it, open enrollment ends December 7, 2026, for coverage starting January 1, 2027.

Can Ro get my Mounjaro covered?

No. Ro doesn't offer Mounjaro, and its free check doesn't include it. Ro's free report can help if your prescriber is considering the Zepbound pen, Wegovy pen, or Ozempic pen instead.

What if I don't know my plan type or the denial reason?

Call the pharmacy-benefits number on your insurance card and ask for the exact reason, the written rule, and the appeal steps. If your coverage is through work, ask HR whether the plan is self-funded. You don't need to guess before you call — use the script above.

What if I'm about to run out?

Contact your prescriber today and tell them how many doses you have left. Ask your plan whether any temporary supply or continued coverage applies, without counting on it. Follow your prescriber's instructions about any gap or change.

Is compounded tirzepatide the same as Mounjaro?

No. Compounded drugs aren't FDA-approved, and the FDA doesn't review them for safety, effectiveness, or quality before they reach patients. Mounjaro's trial results do not establish the safety or effectiveness of a particular compounded product.

Sources

Checked October 21, 2026, unless another date is shown.

• Eli Lilly — Mounjaro Savings & Coverage, full card terms (CMAT-31122 08/2026)
• Eli Lilly — LillyDirect Mounjaro self-pay and purchase terms
• Eli Lilly — Mounjaro prescribing information (revised August 2026) and Zepbound prescribing information
• Eli Lilly — Mounjaro pricing and support information
• Eli Lilly — Zepbound full terms and conditions (CMAT-05333 08/2026; separate Journey and savings-card sections)
• CMS — Medicare GLP-1 Bridge: information for providers
• CMS — Initial Part D exceptions, 2027 Rate Announcement, Table V-2, and Part D benefits manual, transition guidance
• Medicare.gov — Appeals in a Medicare drug plan, Open Enrollment, and Plan Finder
• eCFR — 42 CFR 423.120 (Part D transition supply), 42 CFR 438.420 (Medicaid continued benefits), 29 CFR 2520.104b-3 (benefit-cut summaries), and 29 CFR 2590.715-2715 (SBC change notices)
• HealthCare.gov — Internal appeals and deductible definition
• US Department of Labor — Filing a claim for your health benefits
• Aetna — GLP-1/GIP-GLP-1 policy 2439-C (2026 posting)
• UnitedHealthcare — Commercial GLP-1 prior authorization policy (effective July 1, 2026)
• NIDDK — The A1C Test & Diabetes
• New York Department of Financial Services — external appeal records 202305-163384 and 202305-162818 (2023 decisions)
• NovoCare Pharmacy — Ozempic prices and Pharmacy eligibility terms
• Ro — Mounjaro offering statement, pricing, GLP-1 insurance checker, insurance rules, and terms of use
• Sesame — Mounjaro prescriptions for type 2 diabetes
• Embody — Terms & Conditions and Cancellation & Refund Policy
• IRS — Publication 969: Health Savings Accounts and Other Tax-Favored Health Plans
• FDA — Policies for compounders as GLP-1 supply stabilizes (including April 1, 2026 update), 503A copying guidance, and concerns about unapproved GLP-1 drugs
• Aronne LJ et al. — SURMOUNT-4, JAMA 2024

Still not sure which GLP-1 path fits you? Take The RX Index's free Find My GLP-1 Path quiz — about 2 minutes, no signup.